The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.
Safety and Effectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study
Abstract
Dienogest (DNG) is a progestin with highly selective progesterone activity and known to be effective in the treatment of endometriosis. This prospective cohort study in patients who had been treated with DNG 2 mg (Visanne ® ) for endometriosis was conducted to assess the safety and effectiveness of DNG in a large Korean cohort. This study included 3356 patients with endometriosis from 73 centers in Korea. All patients were treated with DNG 2 mg daily and were followed up for at least 6 months after initial visit. Any adverse events were recorded including severity, onset/closing date, outcomes, treatments, and the causality with DNG. Effectiveness of DNG was measured by changes in visual analogue scale (VAS) from baseline at the end of follow-up. The mean age of the subjects was 34.96 years, and the mean duration of treatment was 285.44 days. Incidence of adverse drug reaction (ADR) was 13.27% (413/3113). The most frequently reported ADR were "abnormal uterine bleeding" 4.14% (129/3113), "increased weight" 2.57% (80/3113), and "headache" 1.22% (38/3113). The number of patients (%) with favorable bleeding patterns was observed to increase as the duration of treatment increases. Amenorrhea was observed in 29.63%, 41.25%, 46.26%, and 53.20% of patients at 3 months, 6 months, 12 months, and more than 12 months follow-up period, respectively. The mean (±SD) VAS change from baseline at the last follow-up visit was -28.19 ± 28.39 mm (P value < 0.0001). This large cohort study confir…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The number of patients with favorable bleeding patterns was observed to increase as the duration of treatment increases, till amenorrhea [204].”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [204]
In the citing paper
“The most frequently reported side effects are abnormal uterine bleeding (4.1%), weight gain (2.5%) and headache (1.2%).”
From Hormonal treatments for endometriosis: The endocrine background (2022) · cites this paper as [204]
Citations
Cites
1 retracted
Gonadotrophin-releasing hormone analogues for pain associated with endometriosis
Prentice, A., Deary, A., Goldbeck-Wood, S., Farquhar, C., & Smith, S. (1999) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd000346 · Cited by 116
RetractedRevised American Society for Reproductive Medicine classification of endometriosis: 1996
American Society for Reproductive Medicine (1997) · Fertility and Sterility · doi:10.1016/s0015-0282(97)81391-x · Cited by 3,018
The global burden of headache: A documentation of headache prevalence and disability worldwide
Stovner, L., Hagen, K., Jensen, R., Katsarava, Z., Lipton, R., Scher, A., Steiner, T., & Zwart, J.-A. (2007) · Cephalalgia · doi:10.1111/j.1468-2982.2007.01288.x · Cited by 2,444
ESHRE guideline: management of women with endometriosis
Dunselman, G. A. J., Vermeulen, N., Becker, C., Calhaz-Jorge, C., D'Hooghe, T., De Bie, B., Heikinheimo, O., Horne, A. W., Kiesel, L., Nap, A., et al. (2014) · Human Reproduction · doi:10.1093/humrep/det457 · Cited by 2,211
ESHRE guideline for the diagnosis and treatment of endometriosis
Kennedy, S., Bergqvist, A., Chapron, C., D’Hooghe, T., Dunselman, G., Greb, R., Hummelshoj, L., Prentice, A., & Saridogan, E. (2005) · Human Reproduction · doi:10.1093/humrep/dei135 · Cited by 1,584
Zondervan, K. T., Becker, C. M., Koga, K., Missmer, S. A., Taylor, R. N., & Viganò, P. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0008-5 · Cited by 1,257
Endometriosis: Epidemiology, Diagnosis and Clinical Management
Parasar, P., Ozcan, P., & Terry, K. L. (2017) · Current Obstetrics and Gynecology Reports · doi:10.1007/s13669-017-0187-1 · Cited by 753
Recurrence of endometriosis and its control
Guo, S.-W. (2009) · Human Reproduction Update · doi:10.1093/humupd/dmp007 · Cited by 719
The social and psychological impact of endometriosis on women's lives: a critical narrative review
Culley, L., Law, C., Hudson, N., Denny, E., Mitchell, H., Baumgarten, M., & Raine-Fenning, N. (2013) · Human Reproduction Update · doi:10.1093/humupd/dmt027 · Cited by 684
Laparoscopic excision of endometriosis: A randomized, placebo-controlled trial
Abbott, J., Hawe, J., Hunter, D., Holmes, M., Finn, P., & Garry, R. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.03.046 · Cited by 502
Research works printed but not linked: 3
- Prentice A, Deary AJ, Bland E. Progestogens and anti-progestogens for pain associated with endometriosis. Cochrane Database Syst Rev. 2000;2:CD002122.
- Oettel M, Carol W, Elger W. A 19-norprogestin without 17a-ethinyl group II: dienogest from a pharmacodynamic point of view. Drugs Today. 1995;31:517–36.
- Guy W. ECDEU Assessment Manual for Psychopharmacology (028 clinical global impressions [CGI]). Rockville: National Institutes of Health; 1976. p. 218–22.
Cited by
Hormonal treatments for endometriosis: The endocrine background
Vannuccini, S., Clemenza, S., Rossi, M., & Petraglia, F. (2022) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09666-w · Cited by 336
Piacenti, I., Viscardi, M. F., Masciullo, L., Sangiuliano, C., Scaramuzzino, S., Piccioni, M. G., Muzii, L., Panici, P. B., & Porpora, M. G. (2021) · Gynecological Endocrinology · doi:10.1080/09513590.2021.1892632 · Cited by 58
Mitchell, J.-B., Chetty, S., & Kathrada, F. (2022) · BMC Women s Health · doi:10.1186/s12905-022-02122-0 · Cited by 58
Tang, H., Lin, T., Wu, M., & Tsai, S. (2024) · Reproductive Medicine and Biology · doi:10.1002/rmb2.12588 · Cited by 49
Maiorana, A., Maranto, M., Restivo, V., Gerfo, D. L., Minneci, G., Mercurio, A., & Incandela, D. (2023) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-023-07271-7 · Cited by 39
Metadata
- Authors
- Cho, B., Roh, J.-W., Park, J., Jeong, K., Kim, T.-H., Kim, Y. S., Kwon, Y.-S., Cho, C.-H., Park, S. H., & Kim, S. H.
- Affiliations
- Dongguk University Ilsan Hospital (KR)
- BongSeng Memorial Hospital (KR)
- Ewha Womans University (KR)
- Soonchunhyang University Hospital Bucheon (KR)
- Soonchunhyang University (KR)
- Ulsan University Hospital (KR)
- Keimyung University (KR)
- Hallym University (KR)
- Asan Medical Center (KR)
- Corresponding author
- Kim, Sung Hoon
- ORCID
- Venue
- Reproductive Sciences
- Published
- 2020-02-12
- Volume
- 27
- Issue
- 3
- Pages
- 905-915
- ISSN
- 1933-7191 (ISSN-L)
- 1933-7205
- OpenAlex
- W3005684753
- Semantic Scholar
- 67625e37ab5ee738acf2bd7bebc498807e032e54
- Cited by
- 44
- References
- 39
- Citations by year
- 2026: 10 · 2025: 7 · 2024: 10 · 2023: 7 · 2022: 6 · 2021: 4
- FWCI
- 3.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Reproductive Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Obstetrics and Gynecology › Ectopic Pregnancy Diagnosis and Management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Menstrual Health and Disorders
- Keywords
- endometriosis, dienogest, adverse drug reactions, abnormal uterine bleeding, amenorrhea, analgesia, treatment safety, treatment effectiveness, Korean patients
- MeSH terms
- Adult, Endometriosis, Female, Hormone Antagonists, Humans, Middle Aged, Nandrolone, Pain, Prospective Studies, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety and Effectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study. https://app.cochat.ai/papers/10.1007/s43032-019-00094-5
- The paper
- Cho, B., Roh, J.-W., Park, J., Jeong, K., Kim, T.-H., Kim, Y. S., Kwon, Y.-S., Cho, C.-H., Park, S. H., & Kim, S. H. (2020). Safety and Effectiveness of Dienogest (Visanne®) for Treatment of Endometriosis: A Large Prospective Cohort Study. Reproductive Sciences. https://doi.org/10.1007/s43032-019-00094-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.